Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
1.560
-0.120 (-7.14%)
At close: Sep 12, 2025, 4:00 PM EDT
1.551
-0.009 (-0.57%)
After-hours: Sep 12, 2025, 7:53 PM EDT
Inhibikase Therapeutics Market Cap
Inhibikase Therapeutics has a market cap or net worth of $116.25 million as of September 12, 2025. Its market cap has increased by 1,012.43% in one year.
Market Cap
116.25M
Enterprise Value
28.62M
1-Year Change
1,012.43%
Ranking
Category
Stock Price
$1.56
Market Cap Chart
Since the IPO on December 23, 2020, Inhibikase Therapeutics's market cap has increased from $100.46M to $116.25M, an increase of 15.72%. That is a compound annual growth rate of 3.14%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Sep 12, 2025 | 116.25M | -46.77% |
| Dec 31, 2024 | 218.38M | 2,684.93% |
| Dec 29, 2023 | 7.84M | -37.83% |
| Dec 30, 2022 | 12.61M | -65.89% |
| Dec 31, 2021 | 36.98M | -46.68% |
| Dec 31, 2020 | 69.35M | -30.96% |
| Dec 23, 2020 | 100.46M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 678.14B |
| Johnson & Johnson | 428.83B |
| AbbVie | 385.71B |
| UnitedHealth Group | 319.26B |
| AstraZeneca | 247.84B |
| Novo Nordisk | 242.99B |
| Novartis AG | 240.09B |
| Abbott Laboratories | 232.75B |